|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Godar DE: Worldwide increasing incidence
of cutaneous malignant melanoma. J Skin Cancer.
2011(858425)2011.
|
|
3
|
Tripp MK, Watson M, Balk SJ, Swetter SM
and Gershenwald JE: State of the science on prevention and
screening to reduce melanoma incidence and mortality: The time is
now. CA Cancer J Clin. 66:460–480. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ribas A, Hamid O, Daud A, Hodi FS, Wolchok
JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, et al:
Association of pembrolizumab with tumor response and survival among
patients with advanced melanoma. JAMA. 315:1600–1609.
2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Long GV, Stroyakovskiy D, Gogas H,
Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A,
Grob JJ, et al: Dabrafenib and trametinib versus dabrafenib and
placebo for Val600 BRAF-mutant melanoma: A multicentre,
double-blind, phase 3 randomised controlled trial. Lancet.
386:444–451. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Pastor-Tomás N, Martínez-Franco A, Bañuls
J, Peñalver JC, Traves V, García-Casado Z, Requena C, Kumar R and
Nagore E: Risk factors for the development of a second melanoma in
patients with cutaneous melanoma. J Eur Acad Dermatol Venereol: Mar
12, 2020 (Online ahead of print).
|
|
7
|
Adler NR, Kelly JW, Haydon A, McLean CA
and Mar VJ: Clinicopathological characteristics and prognosis of
patients with multiple primary melanomas. Br J Dermatol.
178:e44–e45. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Claeson M, Holmström P, Hallberg S,
Gillstedt M, Gonzalez H, Wennberg AM and Paoli J: Multiple primary
melanomas: A common occurrence in Western Sweden. Acta Derm
Venereol. 97:715–719. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
van der Leest RJT, Flohil SC, Arends LR,
de Vries E and Nijsten T: Risk of subsequent cutaneous malignancy
in patients with prior melanoma: A systematic review and
meta-analysis. J Eur Acad Dermatology Venereol. 29:1053–1062.
2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Caini S, Boniol M, Botteri E, Tosti G,
Bazolli B, Russell-Edu W, Giusti F, Testori A and Gandini S: The
risk of developing a second primary cancer in melanoma patients: A
comprehensive review of the literature and meta-analysis. J
Dermatol Sci. 75:3–9. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Bradford PT, Freedman DM, Goldstein AM and
Tucker MA: Increased risk of second primary cancers after a
diagnosis of melanoma. Arch Dermatol. 146:265–272. 2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Spanogle JP, Clarke CA, Aroner S and
Swetter SM: Risk of second primary malignancies following cutaneous
melanoma diagnosis: A population-based study. J Am Acad Dermatol.
62:757–767. 2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Crocetti E, Guzzinati S, Paci E, Falcini
F, Zanetti R, Vercelli M, Rashid I, De Lisi V, Russo A, Vitarelli
S, et al: The risk of developing a second, different, cancer among
14560 survivors of malignant cutaneous melanoma: A study by AIRTUM
(the Italian Network of Cancer Registries). Melanoma Res.
18:230–234. 2008.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bhatia S, Estrada-Batres L, Maryon T,
Bogue M and Chu D: Second primary tumors in patients with cutaneous
malignant melanoma. Cancer. 86:2014–2020. 1999.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Espinosa P, Pfeiffer RM, García-Casado Z,
Requena C, Landi MT, Kumar R and Nagore E: Risk factors for
keratinocyte skin cancer in patients diagnosed with melanoma, a
large retrospective study. Eur J Cancer. 53:115–124.
2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Moore MM, Geller AC, Warton EM, Schwalbe J
and Asgari MM: Multiple primary melanomas among 16,570 patients
with melanoma diagnosed at Kaiser Permanente Northern California,
1996 to 2011. J Am Acad Dermatol. 73:630–636. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Slingluff CL Jr, Vollmer RT and Seigler
HF: Multiple primary melanoma: Incidence and risk factors in 283
patients. Surgery. 113:330–339. 1993.PubMed/NCBI
|
|
18
|
Stam-Posthuma JJ, van Duinen C, Scheffer
E, Vink J and Bergman W: Multiple primary melanomas. J Am Acad
Dermatol. 44:22–27. 2011.
|
|
19
|
Titus-Ernstoff L, Perry AE, Spencer SK,
Gibson J, Ding J, Cole B and Ernstoff MS: Multiple primary
melanoma: Two-year results from a population-based study. Arch
Dermatol. 142:433–438. 2006.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Siskind V, Hughes MC, Palmer JM, Symmons
JM, Aitken JF, Martin NG, Hayward NK and Whiteman DC: Nevi, family
history, and fair skin increase the risk of second primary
melanoma. J Invest Dermatol. 131:461–467. 2011.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Johnson TM, Hamilton T and Lowe L:
Multiple primary melanomas. J Am Acad Dermatol. 39:422–427.
1998.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Vecchiato A, Pasquali S, Menin C, Montesco
MC, Alaibac M, Mocellin S, Campana LG, Nitti D and Rossi CR:
Histopathological characteristics of subsequent melanomas in
patients with multiple primary melanomas. J Eur Acad Dermatol
Venereol. 28:58–64. 2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
DiFronzo LA, Wanek LA and Morton DL:
Earlier diagnosis of second primary melanoma confirms the benefits
of patient education and routine postoperative follow-up. Cancer.
91:1520–1524. 2001.PubMed/NCBI View Article : Google Scholar
|
|
24
|
De Giorgi V, Rossari S, Papi F, Gori A,
Alfaioli B, Grazzini M, Crocetti E, Verdelli A, Foo CW and Lotti T:
Multiple primary melanoma: The impact of atypical naevi and
follow-up. Br J Dermatol. 163:1319–1322. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ilie MA, Caruntu C, Lupu M, Lixandru D,
Tampa M, Georgescu SR, Bastian A, Constantin C, Neagu M, Zurac SA
and Boda D: Current and future applications of confocal laser
scanning microscopy imaging in skin oncology. Oncol Lett.
17:4102–4111. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ancuceanu R, Dinu M, Neaga I, Laszlo FG
and Boda D: Development of QSAR machine learning-based models to
forecast the effect of substances on malignant melanoma cells.
Oncol Lett. 17:4188–4196. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Caruntu C, Boda D, Constantin C, Caruntu A
and Neagu M: Catecholamines increase in vitro proliferation of
murine B16F10 melanoma cells. Acta Endocrinol. 10:545–558.
2014.
|
|
28
|
Boda D: Cellomics as integrative omics for
cancer. Curr Proteomics. 10:237–245. 2013.
|
|
29
|
Stefan O, Tudor G, Constantinescu C, Luca
C, Boda D, Caruntu C, Cioplea M, Nichita L and Zurac SA: E-cadherin
and N-cadherin expression pattern in common melanocytic nevi.
Virchows Archiv. 475 (Suppl)(S28)2019.
|
|
30
|
Zurac S, Neagu M, Constantin C, Cioplea M,
Nedelcu R, Bastian A, Popp C, Nichita L, Andrei R, Tebeica T, et
al: Variations in the expression of TIMP1, TIMP2 and TIMP3 in
cutaneous melanoma with regression and their possible function as
prognostic predictors. Oncol Lett. 11:3354–3360. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Garbe C, Amaral T, Peris K, Hauschild A,
Arenberger P, Bastholt L, Bataille V, Del Marmol V, Dréno B,
Fargnoli MC, et al: European consensus-based interdisciplinary
guideline for melanoma. Part 1: Diagnostics-update 2019. Eur J
Cancer. 126:141–158. 2020.PubMed/NCBI View Article : Google Scholar
|
